BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30997192)

  • 1. Hyperprogressive disease: a distinct effect of immunotherapy?
    Popat V; Gerber DE
    J Thorac Dis; 2019 Mar; 11(Suppl 3):S262-S265. PubMed ID: 30997192
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
    Sun D; Liu D; Liu Q; Hou H
    Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report.
    Xu S; Shukuya T; Shimamura S; Hayashi T; Sato Y; Shiozaki H; Nishioki T; Nishino K; Kato M; Hattori A; Shimada N; Suzuki K; Kitano S; Takahashi K
    Transl Lung Cancer Res; 2024 Mar; 13(3):666-672. PubMed ID: 38601437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Brambilla M; Russo GL; Ferrara R; Manglaviti S; Garassino MC; Occhipinti M
    Explor Target Antitumor Ther; 2020; 1(6):427-433. PubMed ID: 36046388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.
    Li Y; Chen T; Nie TY; Han J; He Y; Tang X; Zhang L
    Front Immunol; 2023; 14():1200875. PubMed ID: 37283759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
    Camelliti S; Le Noci V; Bianchi F; Moscheni C; Arnaboldi F; Gagliano N; Balsari A; Garassino MC; Tagliabue E; Sfondrini L; Sommariva M
    J Exp Clin Cancer Res; 2020 Nov; 39(1):236. PubMed ID: 33168050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic Evolution of Melanocytes Associated With Rapid Clinical Progression of Melanoma: Clinicopathologic Presentation of Hyperprogressive Disease in a Patient Treated With Immunotherapy.
    Almanza J; Dobry A; Ejadi S; Jakowatz J; Lee B
    Am J Dermatopathol; 2022 Dec; 44(12):921-924. PubMed ID: 36395449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
    Toki MI; Syrigos N; Syrigos K
    Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive Disease: Main Features and Key Controversies.
    Arasanz H; Zuazo M; Bocanegra A; Chocarro L; Blanco E; Martínez M; Morilla I; Fernández G; Teijeira L; Morente P; Echaide M; Castro N; Fernández L; Garnica M; Ramos P; Escors D; Kochan G; Vera R
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperprogressive disease: recognizing a novel pattern to improve patient management.
    Champiat S; Ferrara R; Massard C; Besse B; Marabelle A; Soria JC; Ferté C
    Nat Rev Clin Oncol; 2018 Dec; 15(12):748-762. PubMed ID: 30361681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.
    Wei Z; Zhang Y
    Cells; 2022 May; 11(11):. PubMed ID: 35681453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune checkpoint inhibitors-related hyperprogressive disease: a case report].
    Zhang JY; Peng YM; Tan KX; Shen W; Zhang X; Sun CY; Cui HJ
    Zhonghua Zhong Liu Za Zhi; 2021 Sep; 43(9):979-980. PubMed ID: 34530583
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.
    Kurman JS; Murgu SD
    J Thorac Dis; 2018 Feb; 10(2):1124-1128. PubMed ID: 29607190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma.
    Hu CH; Shi S; Dong W; Xiao L; Zang H; Wu F
    Front Oncol; 2022; 12():799549. PubMed ID: 35321429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report.
    Dong S; Liu K; Liu R; Zhuang J
    Exp Ther Med; 2022 Oct; 24(4):617. PubMed ID: 36160895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy.
    Gomes da Morais AL; de Miguel M; Cardenas JM; Calvo E
    Cancer Treat Rev; 2020 Dec; 91():102116. PubMed ID: 33157360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[
    Nakamoto R; C Zaba L; Rosenberg J; Arani Reddy S; W Nobashi T; Ferri V; Davidzon G; Mari Aparici C; Nguyen J; Moradi F; Iagaru A; Lewis Franc B
    Mol Imaging Biol; 2021 Feb; 23(1):139-147. PubMed ID: 32789649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
    Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
    Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.